国际标准期刊号: 2329-9053

分子药剂学与有机过程研究杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • CAS 来源索引 (CASSI)
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • 学术钥匙
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Chitosan Nanoparticles to Increase Natamycin's Candida albicans Inhibitory Effect

Chandasana Gamal

A persistent fungal infection that is common all over the world is fungus keratitis. Even the patient's life and health may be impacted. Natamycin is currently the first-line treatment for fungal keratitis, despite the fact that it has poor water solubility and low drug absorption in clinical settings. To test the viability of using chitosan and NAT together for eye therapy, simple natamycin-chitosan nanoparticles were used. The antifungal property of chitosan NPs was demonstrated by the results to have improved the antifungal effect of NAT. Due to their strong bacteriostasis, NAT-NPs are therefore anticipated to become promising options for the treatment of fungal keratitis.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。